Oncology News
Latest developments with expert commentary
Lifyorli (relacorilant) + nab-paclitaxel for platinum-resistant ovarian cancer
FDA approved relacorilant with nab-paclitaxel. ROSELLA trial: median OS 16.0 vs 11.9 months with significant benefit in overall survival.
Read more →Braftovi (encorafenib) + Erbitux for BRAF V600E colorectal cancer
Targeted approach for first-line treatment. BREAKWATER: median OS 30.3 vs 15.1 months, 51% risk reduction. Personalized strategy.
Read more →Ibrance (palbociclib) in maintenance therapy for HR+ HER2+ breast cancer
PATINA: palbociclib in maintenance phase improved PFS to 44.3 vs 29.1 months. Enhanced approach after induction chemotherapy.
Read more →Tagrisso (osimertinib) + chemotherapy for EGFR-mutated lung cancer
FLAURA2 final analysis: median OS 47.5 vs 37.6 months. Combination with chemotherapy provides meaningful survival benefit.
Read more →Tecentriq (atezolizumab) + mFOLFOX6 for stage 3 dMMR colon cancer
ATOMIC: immunotherapy in adjuvant setting. 3-year RFS 86.3% vs 76.2%, 50% risk reduction for mismatch repair-deficient tumors.
Read more →Do patients need chemotherapy after liver metastasis resection?
JCOG0603: chemotherapy reduces recurrence risk (RFS 49.7% vs 40.5%) but does not improve overall survival. Individualized approach.
Read more →CAR-T Therapy in Oncology. Where It Already Works and Where the Journey Is Just Beginning
CAR-T has become routine for blood cancers. For solid tumors — gliomas, gastric cancer (CLDN18.2), liver cancer (GPC3) — early signals are emerging. I explain who may truly benefit.
Read →Neoadjuvant GOLP for High-Risk Resectable Intrahepatic Cholangiocarcinoma
EFS 18.0 vs 8.7 months, 24-month OS 79% vs 61%. GOLP before surgery improved outcomes in properly selected patients.
Read more →Xtandi + Xofigo in First-Line mCRPC: PEACE-3 Final OS
OS 38.2 vs 32.6 months, HR 0.76. Enzalutamide + radium-223 reduced death risk by 24%.
Read more →Gedatolisib After CDK4/6 Progression in HR+/HER2- Breast Cancer: VIKTORIA-1
PFS 9.3 vs 2.0 months (triplet), HR 0.24. New option for PIK3CA wild-type after CDK4/6 progression.
Read more →Imfinzi Before and After Surgery for Muscle-Invasive Bladder Cancer: NIAGARA
EFS 67.8% vs 59.8%, OS 82.2% vs 75.2%. Perioperative durvalumab improved disease control and overall survival.
Read more →Padcev + Keytruda in First-Line Metastatic Urothelial Cancer: EV-302
PFS 12.5 vs 6.3 months, OS 31.5 vs 16.1 months. Combination reduced death risk by 53% vs chemotherapy.
Read more →Imfinzi + FLOT for Resectable Gastric Cancer: MATTERHORN
EFS 67.4% vs 58.5%, pCR 19.2% vs 7.2%. Adding durvalumab to FLOT reduced event risk by 29%.
Read more →Tagrisso After Chemoradiation for EGFR-Mutant Stage III Lung Cancer: LAURA
Median PFS 39.1 vs 5.6 months. Osimertinib reduced progression risk by 84% in unresectable stage III NSCLC.
Read more →Keytruda + Chemoradiation for Cervical Cancer: KEYNOTE-A18
Adding pembrolizumab to chemoradiation significantly improved PFS and OS in locally advanced cervical cancer.
Read more →Opdivo + Yervoy Before Surgery for Melanoma: NADINA
Neoadjuvant nivolumab + ipilimumab achieved major pathological response in 68.2% of patients with resectable stage III melanoma.
Read more →Opdivo + Yervoy in First-Line MSI-H Colorectal Cancer: CheckMate 8HW
Dual immunotherapy significantly improved PFS vs chemotherapy in microsatellite-unstable colorectal cancer.
Read more →Imfinzi After Chemoradiation for Limited-Stage Small Cell Lung Cancer: ADRIATIC
Durvalumab consolidation significantly improved OS and PFS in limited-stage SCLC after concurrent chemoradiotherapy.
Read more →Dato-DXd as First-Line Treatment for Triple-Negative Breast Cancer: TROPION-Breast02 Results
Dato-DXd improved OS to 23.7 vs 18.7 months and PFS to 10.8 vs 5.6 months in first-line TNBC patients ineligible for immunotherapy. I break down the data and what it means for patients.
Read more →Enhertu After Surgery for HER2-Positive Breast Cancer: What DESTINY-Breast05 Showed
Enhertu reduced the risk of recurrence by 53% compared to T-DM1 in patients with residual disease after neoadjuvant therapy. I break down the data and what it means for patients.
Read more →Pembrolizumab Plus Paclitaxel for Platinum-Resistant Ovarian Cancer: What Changed After FDA Approval
The FDA approved pembrolizumab in combination with paclitaxel for PD-L1-positive platinum-resistant ovarian cancer patients. I discuss who qualifies for this regimen and what it changes.
Read more →New Hormonal Therapy After Surgery for ER-Positive HER2-Negative Breast Cancer: What the Giredestrant Study Showed
The lidERA trial showed that giredestrant improved recurrence-free survival compared to standard hormonal therapy. I break down what this means for patients.
Read more →Enhertu Plus Pertuzumab as First-Line for HER2-Positive Metastatic Breast Cancer: What Changed After FDA Approval
The DESTINY-Breast09 study showed a 44% reduction in progression risk. Median PFS: 40.7 months vs. 26.9 months. I discuss what this means for patients.
Read more →Trodelvy Plus Pembrolizumab as First-Line for PD-L1-Positive Metastatic Triple-Negative Breast Cancer: What ASCENT-04 Showed
Median PFS 11.2 months vs. 7.8 months. 35% reduction in progression risk. The combination entered NCCN as preferred for CPS ≥10.
Read more →Zanidatamab as First-Line for HER2-Positive Gastric Cancer: What the HERIZON-GEA-01 Trial Showed
Median PFS 12.4 months vs. 8.1 months. 35% risk reduction. OS trend: 24.4 vs. 19.2 months. Zanidatamab may become the new standard of care.
Read more →Discuss Your Situation with an Oncologist
News provides general information. For an accurate assessment of your situation, a personal consultation with a review of your medical records is needed. Find answers to common questions on the FAQ page.
By appointment only. Mon–Fri, 10:00–16:00 (MSK).